Psychedelic Science Newsletter
Issue #44July 6, 20267 studies

Psilocybin rewires brain feedback circuits for weeks after a single dose, new evidence shows

Psychedelic research had a busy week, and the most striking result wasn't about the trip itself.

It was about what happens to the brain in the weeks after.

🧠 Psilocybin Loosens the Brain's Top-Down Grip — and the Effect Lingers

  • A preprint combining human EEG data and direct mouse brain recordings found that a single psychedelic dose reduced the brain's tendency to predict and suppress incoming sensory information for up to three weeks afterward. In mice, this coincided with measurable spine growth on neurons in the prefrontal cortex that project down to primary visual cortex.
  • A separate computational modeling study of resting-state brain scans found that four weeks after a full psilocybin dose, fronto-striatal-thalamic circuits became more flexible — with less top-down control and more bottom-up signaling. The shift mapped onto regional serotonin and dopamine receptor availability.
  • Together, these two studies point at the same phenomenon from different angles: psilocybin doesn't just alter the acute experience, it reorganizes feedback architecture in circuits tied to goal-directed behavior and sensory interpretation.

Why it matters: The leading theory of psychedelic therapy has always been that the drug resets rigid mental patterns. Now there's direct circuit-level evidence — in both humans and animals — that the reset is structural, not just experiential.

Key Findings

🍄 Microdosing Psilocybin Didn't Do Much in Rats

  • Rats given sub-perceptual psilocybin doses every other day for five weeks showed no measurable improvement in depression-like behavior, sociability, or novelty-seeking — and no increase in new cell growth in the hippocampus.
  • One small signal did emerge: a slight increase in anxiety-like behavior on the elevated plus maze. The researchers tested behavior 48 hours after each dose to isolate chronic effects from acute ones.
💡 Chronic microdosing produced limited effects in this rat model.
Top 20% journal 🔗 Pharmacology, biochemistry, and behavior 🗓️ Jun 30

🏥 A JAMA Viewpoint Pumps the Brakes on the Psychedelics Executive Order

  • A viewpoint in JAMA addressed the executive order supporting psychedelic drug development, arguing that enthusiasm needs to be matched by ethical guardrails and evidence-based standards before clinical integration.
  • The piece raises the tension between accelerated approval pathways and the readiness of clinical infrastructure to deliver these therapies safely at scale.
💡 Policy momentum is outpacing the clinical readiness evidence base.
🔗 JAMA 🗓️ Jul 1

🧬 Microglia Help Ketamine Build New Brain Connections

  • Mice engineered to lack a key growth factor specifically in their microglia — the brain's immune cells — showed blunted behavioral responses to ketamine and failed to grow new dendritic spines in the prefrontal cortex after a dose.
  • The finding implicates microglia as active participants in ketamine's antidepressant mechanism, not just bystanders, and points to a growth-factor signaling pathway as a necessary link.
💡 Ketamine's spine-building effect in the prefrontal cortex requires microglial support.

🌐 Community-Co-Designed Psilocybin Trial Launches in New Mexico

  • Researchers at the University of New Mexico, working with a county health equity council and a national psychedelic access alliance, designed an FDA-approved group psilocybin therapy study for PTSD — using whole psilocybin mushroom chocolates rather than synthesized psilocybin.
  • Six groups of six participants will include veterans, first responders, and women survivors of sexual violence. A parallel micro-costing study will track what it actually costs to deliver this model of care.
💡 This trial embeds equity and real-world cost analysis from the start.
Top 20% journal 🔗 Frontiers in public health 🗓️ Jul 3

🧒 Psilocybin Trial Protocol Published for Adolescents With Anorexia

  • A study protocol was published for a psilocybin trial targeting anorexia nervosa in adolescents and young adults — a population with high relapse rates and limited effective treatment options.
  • Anorexia shares cognitive rigidity with other conditions where psilocybin has shown early promise, making it a plausible target, though clinical evidence in this age group is currently limited.
💡 A formal protocol now exists for one of psilocybin's most cautious frontiers.
Top 30% journal 🔗 PloS one 🗓️ Jun 30

🔒 Consent Forms for Ketamine Trials Are Too Hard to Read

  • A cross-sectional analysis of informed consent documents from ketamine mental health trials on ClinicalTrials.gov found that readability is a systematic problem — particularly concerning because the patients enrolling in these trials may have cognitive or affective symptoms that already compromise their ability to parse dense text.
  • The study raises a core ethical question: if participants can't understand what they're agreeing to, the consent process isn't functioning as intended.
💡 Ketamine trial consent forms aren't readable enough for the populations they enroll.
Top 20% journal 🔗 Therapeutic advances in psychopharmacology 🗓️ Jul 2

Implications

The circuit-level evidence for lasting psychedelic effects is converging fast — from human EEG to mouse electrodes to computational brain modeling. The unresolved tension: none of these studies can yet tell us whether the same reorganization that looks therapeutic in some people might look destabilizing in others.

Studies in this issue

Primary sources used for this newsletter.

  1. Psychedelics reduce brain prediction signals after use by changing connections between thinking areas
    main storybioRxiv : the preprint server for biology2026-06-29PMID 42367980
  2. Long-term low-dose psilocin has small effects on behavior and does not increase new brain cell growth in rats
    key findingPharmacology, biochemistry, and behavior2026-06-30PMID 42379524
  3. Government Approval and Medical Preparedness for Psychedelic Therapies
    key findingJAMA2026-07-01PMID 42384415
  4. Microglia-produced BDNF helps ketamine improve behavior and brain cell connections
    key findingBrain, behavior, and immunity2026-07-02PMID 42392461
  5. Community involvement as a basis for research on group psilocybin therapy in New Mexico
    key findingFrontiers in public health2026-07-03PMID 42395285
  6. Testing the safety and potential benefits of psilocybin for treating anorexia in teens and young adults
    key findingPloS one2026-06-30PMID 42378255
  7. How easy to understand are consent forms for ketamine trials in mental health
    key findingTherapeutic advances in psychopharmacology2026-07-02PMID 42388555

Continue reading

All Psychedelic Science issues